Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study

Aim The efficacy and safety of simeprevir in combination with peginterferon‐α‐2b and ribavirin (PEG IFN‐α‐2b/RBV) were investigated in patients infected with hepatitis C virus (HCV) genotype 1 who were treatment‐naïve or had previously received interferon (IFN)‐based therapy. Methods CONCERTO‐4 (NCT...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hepatology research 2015-05, Vol.45 (5), p.501-513
Hauptverfasser:	Kumada, Hiromitsu, Hayashi, Norio, Izumi, Namiki, Okanoue, Takeshi, Tsubouchi, Hirohito, Yatsuhashi, Hiroshi, Kato, Mai, Rito, Ki, Komada, Yuji, Seto, Chiharu, Goto, Shoichiro
Format:	Artikel
Sprache:	eng
Schlagworte:	chronic hepatitis C direct-acting antiviral protease inhibitor simeprevir (TMC435) sustained virologic response
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!